Boji Pharmaceuticals announced that the "glucosamine sulfate sodium chloride double salt" declared by the subsidiary Science Park Company was approved and issued by the State Drug Administration with the Notice of Approval of the Application for the Listing of Chemical APIs. The API has anti-inflammatory effect and can be used to produce related dosage forms. This approval will help to broaden the company's business areas and enhance its competitiveness, but it will not have a significant impact on its business performance at present.
